Bioscience & Pharmaceutical

The University of Delaware is bracing itself for apparent freezes in funding, while there is great uncertainty around federal funding.

A Chinese pharmaceutical company is steadily preparing for its $515 million Middletown campus as Delaware officials continue to wait on whether or not Merck will select the state for its next pharmaceutical plant.

Initiatives like maximizing capital investment and working to develop a board to improve STEM skill training are top of the Delaware Bioscience Association's agenda.

The Delaware state investment board has approved a $30.2 million taxpayer-funded grant to Merck & Company Monday, signaling that the pharmaceutical giant may be building a major factory at the Chestnut Run Innovation and Science Park (CRISP).

With a proposed cap on indirect costs for NIH grants, Delaware's life science sector could be hit the next generation of start-ups.

Pharmaceutical juggernaut Merck is seeking a $30 million state grant from Delaware to open a facility in Wilmington, though its exact location has yet to be confirmed.

Prelude CFO Bryant Lim had stepped in the role after Prelude’s previous top financial executive stepped down from the post in April.

The MRA Group believes the "live, work, play" campus is resonating with potential life science tenants, and the hotel at CRISP will help achieve that.

EastSide Charter School is adopting an innovative strategy to prepare kids in the Riverside community for the jobs of tomorrow, at a time when the Delaware life sciences sector needs a trained workforce.

Noramco, a drug manufacturer in downtown Wilmington, has sold the land and building, and signed a 20-year lease with Fortress Investment Group.